TWI422587B - Ａｋｔ及ｐ７０ｓ６激酶抑制劑 - Google Patents

Ａｋｔ及ｐ７０ｓ６激酶抑制劑 Download PDF

Info

Publication number: TWI422587B
Authority: TW; Taiwan
Prior art keywords: compound; phenyl; ethyl; imidazol; fluoro
Prior art date: 2008-11-11

Application number

TW098136731A

Other languages

English (en)

Chinese (zh)

Other versions

TW201022268A (en

Inventor

Robert Dean Dally

Sajan Joseph

Timothy Alan Shepherd

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-11

Filing date

2009-10-29

Publication date

2014-01-11

2009-10-29 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2010-06-16 Publication of TW201022268A publication Critical patent/TW201022268A/zh

2014-01-11 Application granted granted Critical

2014-01-11 Publication of TWI422587B publication Critical patent/TWI422587B/zh

Links

108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 title description 13
229940043355 kinase inhibitor Drugs 0.000 title description 7
239000003757 phosphotransferase inhibitor Substances 0.000 title description 7
150000001875 compounds Chemical class 0.000 claims description 166
-1 2-methyl-4-thiazolyl Chemical group 0.000 claims description 60
150000003839 salts Chemical class 0.000 claims description 49
229910052757 nitrogen Inorganic materials 0.000 claims description 27
229910052739 hydrogen Inorganic materials 0.000 claims description 24
229910052799 carbon Inorganic materials 0.000 claims description 23
125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
229910052801 chlorine Inorganic materials 0.000 claims description 20
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 19
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 10
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
201000010915 Glioblastoma multiforme Diseases 0.000 claims description 9
208000005017 glioblastoma Diseases 0.000 claims description 9
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 9
125000003386 piperidinyl group Chemical group 0.000 claims description 8
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims description 7
229910052731 fluorine Inorganic materials 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 4
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
125000002393 azetidinyl group Chemical group 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 350
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 141
238000002360 preparation method Methods 0.000 description 101
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 91
235000019439 ethyl acetate Nutrition 0.000 description 91
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
238000006243 chemical reaction Methods 0.000 description 62
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 60
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 51
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
239000000243 solution Substances 0.000 description 47
239000000543 intermediate Substances 0.000 description 45
238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 43
239000012044 organic layer Substances 0.000 description 41
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 40
239000012267 brine Substances 0.000 description 39
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
238000003756 stirring Methods 0.000 description 30
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
239000000203 mixture Substances 0.000 description 27
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
239000007787 solid Substances 0.000 description 25
238000000034 method Methods 0.000 description 21
239000000460 chlorine Substances 0.000 description 20
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 20
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 20
229910000041 hydrogen chloride Inorganic materials 0.000 description 20
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
229920006395 saturated elastomer Polymers 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 17
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
206010028980 Neoplasm Diseases 0.000 description 16
PKKYYNMRPXEIFE-UHFFFAOYSA-N 4-chloro-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound ClC1=NC=NC2=C1CC(=O)N2 PKKYYNMRPXEIFE-UHFFFAOYSA-N 0.000 description 14
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
238000005481 NMR spectroscopy Methods 0.000 description 14
108091008611 Protein Kinase B Proteins 0.000 description 14
239000010410 layer Substances 0.000 description 14
102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
201000011510 cancer Diseases 0.000 description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
239000002585 base Substances 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
150000001412 amines Chemical group 0.000 description 10
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 9
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
239000012074 organic phase Substances 0.000 description 9
238000000746 purification Methods 0.000 description 9
239000002904 solvent Substances 0.000 description 9
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
YDFKZIGAUIKZGP-UHFFFAOYSA-N 4-[4-[1-[2-(dimethylamino)ethyl]-4-[4-fluoro-3-(trifluoromethyl)phenyl]imidazol-2-yl]piperidin-1-yl]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(C2CCN(CC2)C=2C=3CC(=O)NC=3N=CN=2)N(CCN(C)C)C=C1C1=CC=C(F)C(C(F)(F)F)=C1 YDFKZIGAUIKZGP-UHFFFAOYSA-N 0.000 description 8
239000005909 Kieselgur Substances 0.000 description 8
241000124008 Mammalia Species 0.000 description 8
235000019270 ammonium chloride Nutrition 0.000 description 8
239000012141 concentrate Substances 0.000 description 8
235000008504 concentrate Nutrition 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
239000011734 sodium Substances 0.000 description 8
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 7
238000001704 evaporation Methods 0.000 description 7
230000008020 evaporation Effects 0.000 description 7
238000001914 filtration Methods 0.000 description 7
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
208000021519 Hodgkin lymphoma Diseases 0.000 description 6
208000010747 Hodgkins lymphoma Diseases 0.000 description 6
206010041067 Small cell lung cancer Diseases 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000013058 crude material Substances 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 6
208000000587 small cell lung carcinoma Diseases 0.000 description 6
125000001424 substituent group Chemical group 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
229940124597 therapeutic agent Drugs 0.000 description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000033115 angiogenesis Effects 0.000 description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000003197 protein kinase B inhibitor Substances 0.000 description 5
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 5
238000010992 reflux Methods 0.000 description 5
229960002930 sirolimus Drugs 0.000 description 5
229910000104 sodium hydride Inorganic materials 0.000 description 5
238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 4
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
BUNOSKWLVXNWEH-UHFFFAOYSA-N 2-bromo-1-[4-fluoro-3-(trifluoromethyl)phenyl]ethanone Chemical compound FC1=CC=C(C(=O)CBr)C=C1C(F)(F)F BUNOSKWLVXNWEH-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
239000002168 alkylating agent Substances 0.000 description 4
229940100198 alkylating agent Drugs 0.000 description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000000284 extract Substances 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
150000002576 ketones Chemical class 0.000 description 4
ORHWGOUAAWDYFP-UHFFFAOYSA-N methyl 2-(4,6-dichloropyrimidin-5-yl)acetate Chemical compound COC(=O)CC1=C(Cl)N=CN=C1Cl ORHWGOUAAWDYFP-UHFFFAOYSA-N 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
238000000634 powder X-ray diffraction Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 4
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 3
GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 3
SMFKBTCLCQAAOD-UHFFFAOYSA-N 2-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-2-piperidin-4-ylimidazol-1-yl]-n,n-dimethylethanamine;dihydrochloride Chemical compound Cl.Cl.CN(C)CCN1C=C(C=2C=C(C(F)=CC=2)C(F)(F)F)N=C1C1CCNCC1 SMFKBTCLCQAAOD-UHFFFAOYSA-N 0.000 description 3
LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 3
YAKDLOKTVMXZQG-VQCQRNETSA-N 4-[4-[4-[3-(difluoromethyl)-4-fluorophenyl]-1-[[(2r)-1-methylpiperidin-2-yl]methyl]imidazol-2-yl]piperidin-1-yl]-5-ethyl-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(CC)C(=O)NC2=NC=NC=1N(CC1)CCC1C1=NC(C=2C=C(C(F)=CC=2)C(F)F)=CN1C[C@H]1CCCCN1C YAKDLOKTVMXZQG-VQCQRNETSA-N 0.000 description 3
KYBINFJRIXEZGI-UHFFFAOYSA-N 4-chloro-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C1=NC(Cl)=C2C(C)(C)C(=O)NC2=N1 KYBINFJRIXEZGI-UHFFFAOYSA-N 0.000 description 3
IJONSWCCVQAUMH-UHFFFAOYSA-N 5,5-dibromo-4-chloro-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound ClC1=NC=NC2=C1C(Br)(Br)C(=O)N2 IJONSWCCVQAUMH-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
OXPPBAZPBDFZGP-UHFFFAOYSA-N CN(C(N(N)C)=N)C.CN(C(N(N)C)=N)C.[Li] Chemical compound CN(C(N(N)C)=N)C.CN(C(N(N)C)=N)C.[Li] OXPPBAZPBDFZGP-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
208000017604 Hodgkin disease Diseases 0.000 description 3
208000017662 Hodgkin disease lymphocyte depletion type stage unspecified Diseases 0.000 description 3
208000007766 Kaposi sarcoma Diseases 0.000 description 3
208000034578 Multiple myelomas Diseases 0.000 description 3
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
206010033128 Ovarian cancer Diseases 0.000 description 3
206010061535 Ovarian neoplasm Diseases 0.000 description 3
206010061902 Pancreatic neoplasm Diseases 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
208000006265 Renal cell carcinoma Diseases 0.000 description 3
CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000012300 argon atmosphere Substances 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
201000010897 colon adenocarcinoma Diseases 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
239000003480 eluent Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
239000005457 ice water Substances 0.000 description 3
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
SIJXBVAZZBKSKE-UHFFFAOYSA-N methyl 2-(4-hydroxy-6-oxo-1h-pyrimidin-5-yl)acetate Chemical compound COC(=O)CC1=C(O)N=CN=C1O SIJXBVAZZBKSKE-UHFFFAOYSA-N 0.000 description 3
PYIXYEMKFUOLDQ-UHFFFAOYSA-N n-benzyl-2-chloro-n-methylethanamine;hydrochloride Chemical compound [Cl-].ClCC[NH+](C)CC1=CC=CC=C1 PYIXYEMKFUOLDQ-UHFFFAOYSA-N 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
201000002528 pancreatic cancer Diseases 0.000 description 3
208000008443 pancreatic carcinoma Diseases 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
BQWIIWXJLRPGFE-UHFFFAOYSA-N tert-butyl 4-[4-(3-chloro-4-fluorophenyl)-1-(cyanomethyl)imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(Cl)C(F)=CC=2)=CN1CC#N BQWIIWXJLRPGFE-UHFFFAOYSA-N 0.000 description 3
ZTWUNSDSBMTLNL-UHFFFAOYSA-N tert-butyl 4-[5-(3-chloro-4-fluorophenyl)-1h-imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(Cl)C(F)=CC=2)=CN1 ZTWUNSDSBMTLNL-UHFFFAOYSA-N 0.000 description 3
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
DSOGZRRUOVMSTQ-MRXNPFEDSA-N (3r)-3-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-2-piperidin-4-ylimidazol-1-yl]-1-methylpiperidine Chemical compound C1N(C)CCC[C@H]1N1C(C2CCNCC2)=NC(C=2C=C(C(F)=CC=2)C(F)(F)F)=C1 DSOGZRRUOVMSTQ-MRXNPFEDSA-N 0.000 description 2
SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 2
ROUYUBHVBIKMQO-UHFFFAOYSA-N 1,4-diiodobutane Chemical compound ICCCCI ROUYUBHVBIKMQO-UHFFFAOYSA-N 0.000 description 2
BKWCCUMGBGQTHN-UHFFFAOYSA-N 2-[4-(3-chloro-4-fluorophenyl)imidazol-1-yl]-n,n-dimethylethanamine Chemical compound CN(C)CCN1C=NC(C=2C=C(Cl)C(F)=CC=2)=C1 BKWCCUMGBGQTHN-UHFFFAOYSA-N 0.000 description 2
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
KLFYPDKDZRLLHM-UHFFFAOYSA-N 4,6-dichloro-n-methylpyrimidin-5-amine Chemical compound CNC1=C(Cl)N=CN=C1Cl KLFYPDKDZRLLHM-UHFFFAOYSA-N 0.000 description 2
NIGDWBHWHVHOAD-UHFFFAOYSA-N 4,6-dichloropyrimidin-5-amine Chemical compound NC1=C(Cl)N=CN=C1Cl NIGDWBHWHVHOAD-UHFFFAOYSA-N 0.000 description 2
VYZVKIURUVBXNH-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluorophenyl)-1-[2-(dimethylamino)ethyl]imidazol-2-yl]piperidine-1-carboxylic acid Chemical compound ClC=1C=C(C=CC=1F)C=1N=C(N(C=1)CCN(C)C)C1CCN(CC1)C(=O)O VYZVKIURUVBXNH-UHFFFAOYSA-N 0.000 description 2
XNHZUEXNUPLTNY-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluorophenyl)-1-[2-(methylamino)ethyl]imidazol-2-yl]piperidine-1-carboxylic acid Chemical compound ClC=1C=C(C=CC=1F)C=1N=C(N(C=1)CCNC)C1CCN(CC1)C(=O)O XNHZUEXNUPLTNY-UHFFFAOYSA-N 0.000 description 2
GMBNVNIGFHWFGC-UHFFFAOYSA-N 4-[4-[1-[2-(dimethylamino)ethyl]-4-[4-fluoro-3-(trifluoromethyl)phenyl]imidazol-2-yl]piperidin-1-yl]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one;hydrate Chemical compound O.N1=C(C2CCN(CC2)C=2C=3CC(=O)NC=3N=CN=2)N(CCN(C)C)C=C1C1=CC=C(F)C(C(F)(F)F)=C1 GMBNVNIGFHWFGC-UHFFFAOYSA-N 0.000 description 2
HQYFVTBDSPQOTE-UHFFFAOYSA-N 4-[4-[4-(3,4-difluorophenyl)-1-(2-pyrrolidin-1-ylethyl)imidazol-2-yl]piperidin-1-yl]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound C1=C(F)C(F)=CC=C1C(N=C1C2CCN(CC2)C=2C=3CC(=O)NC=3N=CN=2)=CN1CCN1CCCC1 HQYFVTBDSPQOTE-UHFFFAOYSA-N 0.000 description 2
IQKBJMXJOQXLEC-UHFFFAOYSA-N 4-chloro-5-ethyl-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound C1=NC(Cl)=C2C(CC)C(=O)NC2=N1 IQKBJMXJOQXLEC-UHFFFAOYSA-N 0.000 description 2
KYMNDJBNPVFKDS-UHFFFAOYSA-N 4-chloro-7-[(2,4-dimethoxyphenyl)methyl]-5h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound COC1=CC(OC)=CC=C1CN1C(N=CN=C2Cl)=C2CC1=O KYMNDJBNPVFKDS-UHFFFAOYSA-N 0.000 description 2
NKVRBGHVUINDMZ-UHFFFAOYSA-N 4-chloro-7-[(4-methoxyphenyl)methyl]-5h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C1=CC(OC)=CC=C1CN1C(N=CN=C2Cl)=C2CC1=O NKVRBGHVUINDMZ-UHFFFAOYSA-N 0.000 description 2
BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 2
JJRDAGZSVMIJFP-UHFFFAOYSA-N 6-chloro-5-n-methylpyrimidine-4,5-diamine Chemical compound CNC1=C(N)N=CN=C1Cl JJRDAGZSVMIJFP-UHFFFAOYSA-N 0.000 description 2
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
UAFAYXBFJAHVOU-UHFFFAOYSA-N BrCCOC(C(C)(C)C(C)(C)C)CCCCCCCC Chemical compound BrCCOC(C(C)(C)C(C)(C)C)CCCCCCCC UAFAYXBFJAHVOU-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
241000195493 Cryptophyta Species 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
102000001301 EGF receptor Human genes 0.000 description 2
108060006698 EGF receptor Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 2
OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
MWAREVYCFWUDTM-UHFFFAOYSA-N [2-[4-fluoro-3-(trifluoromethyl)phenyl]-2-oxoethyl]azanium;chloride Chemical compound Cl.NCC(=O)C1=CC=C(F)C(C(F)(F)F)=C1 MWAREVYCFWUDTM-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
239000011260 aqueous acid Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000012043 crude product Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000001035 drying Methods 0.000 description 2
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
VEIWYFRREFUNRC-UHFFFAOYSA-N hydron;piperidine;chloride Chemical compound [Cl-].C1CC[NH2+]CC1 VEIWYFRREFUNRC-UHFFFAOYSA-N 0.000 description 2
125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 2
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
NIGZBZBAGCSDGV-UHFFFAOYSA-N methyl 2-[4-chloro-6-[(4-methoxyphenyl)methylamino]pyrimidin-5-yl]acetate Chemical compound COC(=O)CC1=C(Cl)N=CN=C1NCC1=CC=C(OC)C=C1 NIGZBZBAGCSDGV-UHFFFAOYSA-N 0.000 description 2
201000011519 neuroendocrine tumor Diseases 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
229960001972 panitumumab Drugs 0.000 description 2
230000037361 pathway Effects 0.000 description 2
WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 2
239000012071 phase Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
229960005235 piperonyl butoxide Drugs 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
UEXZYUUKJQPTCQ-UHFFFAOYSA-N pyridin-1-ium;bromide;hydrobromide Chemical compound Br.Br.C1=CC=NC=C1 UEXZYUUKJQPTCQ-UHFFFAOYSA-N 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
UTUVUXYKFFKIKP-UHFFFAOYSA-N tert-butyl 4-(1h-imidazol-2-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC=CN1 UTUVUXYKFFKIKP-UHFFFAOYSA-N 0.000 description 2
JDSMVUPKXPLSFO-UHFFFAOYSA-N tert-butyl 4-[4-bromo-1-(2-hydroxyethyl)imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(Br)=CN1CCO JDSMVUPKXPLSFO-UHFFFAOYSA-N 0.000 description 2
HTCKTMUPXPTSTF-UHFFFAOYSA-N tert-butyl 4-[4-bromo-1-(2-methylsulfonyloxyethyl)imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(Br)=CN1CCOS(C)(=O)=O HTCKTMUPXPTSTF-UHFFFAOYSA-N 0.000 description 2
BQBLWHOSZXQOGF-UHFFFAOYSA-N tert-butyl 4-[4-bromo-1-[2-(dimethylamino)ethyl]imidazol-2-yl]piperidine-1-carboxylate Chemical compound CN(C)CCN1C=C(Br)N=C1C1CCN(C(=O)OC(C)(C)C)CC1 BQBLWHOSZXQOGF-UHFFFAOYSA-N 0.000 description 2
LQIWHTXBOSZKMH-UHFFFAOYSA-N tert-butyl 4-[5-(3,4-difluorophenyl)-1h-imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(F)C(F)=CC=2)=CN1 LQIWHTXBOSZKMH-UHFFFAOYSA-N 0.000 description 2
DLLYEBNXXOZNAR-UHFFFAOYSA-N tert-butyl 4-[5-[4-fluoro-3-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(C(F)=CC=2)C(F)(F)F)=CN1 DLLYEBNXXOZNAR-UHFFFAOYSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
TVWZLLYAJDSSCJ-UHFFFAOYSA-N triethyl ethane-1,1,2-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)C(=O)OCC TVWZLLYAJDSSCJ-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
DVWJFTGEISXVSH-CWVFEVJCSA-N (1R,3S,5S,7Z,11R,12S,13Z,15Z,17Z,19Z,21R,23S,24R,25S)-21-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-12-ethyl-1,3,5,25-tetrahydroxy-11-methyl-9-oxo-10,27-dioxabicyclo[21.3.1]heptacosa-7,13,15,17,19-pentaene-24-carboxylic acid Chemical compound CC[C@H]1\C=C/C=C\C=C/C=C\[C@@H](C[C@@H]2O[C@@](O)(C[C@H](O)[C@H]2C(O)=O)C[C@@H](O)C[C@@H](O)C\C=C/C(=O)O[C@@H]1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O DVWJFTGEISXVSH-CWVFEVJCSA-N 0.000 description 1
LYJHYXLNDKWVBC-QGZVFWFLSA-N (2r)-2-[[4-[3-(difluoromethyl)-4-fluorophenyl]-2-piperidin-4-ylimidazol-1-yl]methyl]-1-methylpiperidine Chemical compound CN1CCCC[C@@H]1CN1C(C2CCNCC2)=NC(C=2C=C(C(F)=CC=2)C(F)F)=C1 LYJHYXLNDKWVBC-QGZVFWFLSA-N 0.000 description 1
PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
ZGTFNNUASMWGTM-UHFFFAOYSA-N 1,3-thiazole-2-carbaldehyde Chemical compound O=CC1=NC=CS1 ZGTFNNUASMWGTM-UHFFFAOYSA-N 0.000 description 1
GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 1
PIMNFNXBTGPCIL-UHFFFAOYSA-N 1-(2-bromophenyl)ethanone Chemical class CC(=O)C1=CC=CC=C1Br PIMNFNXBTGPCIL-UHFFFAOYSA-N 0.000 description 1
IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 1
WOGOXEPEEXSPAF-UHFFFAOYSA-N 1h-imidazole;piperidine Chemical compound C1=CNC=N1.C1CCNCC1 WOGOXEPEEXSPAF-UHFFFAOYSA-N 0.000 description 1
QPAJMCIIAGNHFV-UHFFFAOYSA-N 2-[4-(3-chloro-4-fluorophenyl)-2-piperidin-4-ylimidazol-1-yl]-n,n-dimethylethanamine;dihydrochloride Chemical compound Cl.Cl.CN(C)CCN1C=C(C=2C=C(Cl)C(F)=CC=2)N=C1C1CCNCC1 QPAJMCIIAGNHFV-UHFFFAOYSA-N 0.000 description 1
KIABTEBJJQSDSG-UHFFFAOYSA-N 2-[4-(3-chloro-4-fluorophenyl)-2-piperidin-4-ylimidazol-1-yl]acetonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.C1=C(Cl)C(F)=CC=C1C1=CN(CC#N)C(C2CCNCC2)=N1 KIABTEBJJQSDSG-UHFFFAOYSA-N 0.000 description 1
JCKVHXDCXAACKU-UHFFFAOYSA-N 2-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-2-piperidin-4-ylimidazol-1-yl]-n,n-dimethylethanamine Chemical compound CN(C)CCN1C=C(C=2C=C(C(F)=CC=2)C(F)(F)F)N=C1C1CCNCC1 JCKVHXDCXAACKU-UHFFFAOYSA-N 0.000 description 1
WOUANPHGFPAJCA-UHFFFAOYSA-N 2-[benzyl(methyl)amino]ethanol Chemical compound OCCN(C)CC1=CC=CC=C1 WOUANPHGFPAJCA-UHFFFAOYSA-N 0.000 description 1
WZPSNPSAYYCJGX-UHFFFAOYSA-N 2-amino-1-[4-fluoro-3-(trifluoromethyl)phenyl]ethanone Chemical compound NCC(=O)C1=CC=C(F)C(C(F)(F)F)=C1 WZPSNPSAYYCJGX-UHFFFAOYSA-N 0.000 description 1
REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
OJCGLYYANKVUEM-UHFFFAOYSA-N 2-bromopyridin-1-ium;bromide Chemical compound Br.BrC1=CC=CC=N1 OJCGLYYANKVUEM-UHFFFAOYSA-N 0.000 description 1
DSKKEOXRMGSCSN-UHFFFAOYSA-N 3-aminopiperidine-1-carboxylic acid Chemical compound NC1CCCN(C(O)=O)C1 DSKKEOXRMGSCSN-UHFFFAOYSA-N 0.000 description 1
IZJRNEBBAZPVPA-UHFFFAOYSA-N 4-[4-(3,4-difluorophenyl)-1-[2-(dimethylamino)ethyl]imidazol-2-yl]piperidine-1-carboxylic acid Chemical compound FC=1C=C(C=CC=1F)C=1N=C(N(C=1)CCN(C)C)C1CCN(CC1)C(=O)O IZJRNEBBAZPVPA-UHFFFAOYSA-N 0.000 description 1
IPPRHZFQVVBAKE-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluorophenyl)-1-(2-methylsulfonyloxyethyl)imidazol-2-yl]piperidine-1-carboxylic acid Chemical compound ClC=1C=C(C=CC=1F)C=1N=C(N(C=1)CCOS(=O)(=O)C)C1CCN(CC1)C(=O)O IPPRHZFQVVBAKE-UHFFFAOYSA-N 0.000 description 1
NCDUODGJJGQYPA-UHFFFAOYSA-N 4-[4-[1-(2-aminoethyl)-4-[4-fluoro-3-(trifluoromethyl)phenyl]imidazol-2-yl]piperidin-1-yl]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(C2CCN(CC2)C=2C=3CC(=O)NC=3N=CN=2)N(CCN)C=C1C1=CC=C(F)C(C(F)(F)F)=C1 NCDUODGJJGQYPA-UHFFFAOYSA-N 0.000 description 1
PVZWSMBDDGFHOM-UHFFFAOYSA-N 4-[4-[4-(3,4-difluorophenyl)-1-[2-(dimethylamino)ethyl]imidazol-2-yl]piperidin-1-yl]-5-ethyl-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(CC)C(=O)NC2=NC=NC=1N(CC1)CCC1C(N(C=1)CCN(C)C)=NC=1C1=CC=C(F)C(F)=C1 PVZWSMBDDGFHOM-UHFFFAOYSA-N 0.000 description 1
VYBKOCQIMLJOHU-UHFFFAOYSA-N 4-[4-[4-(3,4-difluorophenyl)-1-[2-(dimethylamino)ethyl]imidazol-2-yl]piperidin-1-yl]-5-methyl-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(C)C(=O)NC2=NC=NC=1N(CC1)CCC1C(N(C=1)CCN(C)C)=NC=1C1=CC=C(F)C(F)=C1 VYBKOCQIMLJOHU-UHFFFAOYSA-N 0.000 description 1
BZINICBYGWKSIJ-UHFFFAOYSA-N 4-[4-[4-(3-chloro-4-fluorophenyl)-1-(2-pyrrolidin-1-ylethyl)imidazol-2-yl]piperidin-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(C)(C)C(=O)NC2=NC=NC=1N(CC1)CCC1C1=NC(C=2C=C(Cl)C(F)=CC=2)=CN1CCN1CCCC1 BZINICBYGWKSIJ-UHFFFAOYSA-N 0.000 description 1
JRVPQJNMNZJKEF-UHFFFAOYSA-N 4-[4-[4-(3-chloro-4-fluorophenyl)-1-(2-pyrrolidin-1-ylethyl)imidazol-2-yl]piperidin-1-yl]-5-methyl-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(C)C(=O)NC2=NC=NC=1N(CC1)CCC1C1=NC(C=2C=C(Cl)C(F)=CC=2)=CN1CCN1CCCC1 JRVPQJNMNZJKEF-UHFFFAOYSA-N 0.000 description 1
SVUPWZQTWWEMIF-UHFFFAOYSA-N 4-[4-[4-(3-chloro-4-fluorophenyl)-1-[2-(dimethylamino)ethyl]imidazol-2-yl]piperidin-1-yl]-5-(pyridin-4-ylmethylidene)-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound CN(C)CCN1C=C(C=2C=C(Cl)C(F)=CC=2)N=C1C(CC1)CCN1C(C1=2)=NC=NC=2NC(=O)C1=CC1=CC=NC=C1 SVUPWZQTWWEMIF-UHFFFAOYSA-N 0.000 description 1
UGLXRLWXQXKGFX-GMUIIQOCSA-N 4-[4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(3r)-1-methylpiperidin-3-yl]imidazol-2-yl]piperidin-1-yl]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one;hydrochloride Chemical compound Cl.C1N(C)CCC[C@H]1N1C(C2CCN(CC2)C=2C=3CC(=O)NC=3N=CN=2)=NC(C=2C=C(C(F)=CC=2)C(F)(F)F)=C1 UGLXRLWXQXKGFX-GMUIIQOCSA-N 0.000 description 1
QUDAHTWBLHVGCG-UHFFFAOYSA-N 4-[4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[2-(methylamino)ethyl]imidazol-2-yl]piperidin-1-yl]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(C2CCN(CC2)C=2C=3CC(=O)NC=3N=CN=2)N(CCNC)C=C1C1=CC=C(F)C(C(F)(F)F)=C1 QUDAHTWBLHVGCG-UHFFFAOYSA-N 0.000 description 1
DHWKJPCGURFZBE-UHFFFAOYSA-N 4-[4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[2-[methyl(propan-2-yl)amino]ethyl]imidazol-2-yl]piperidin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine-5,6-dione;hydrochloride Chemical compound Cl.N1=C(C2CCN(CC2)C=2C=3C(=O)C(=O)NC=3N=CN=2)N(CCN(C)C(C)C)C=C1C1=CC=C(F)C(C(F)(F)F)=C1 DHWKJPCGURFZBE-UHFFFAOYSA-N 0.000 description 1
AZVOJDLBZIWNNO-UHFFFAOYSA-N 4-[4-bromo-1-[2-(oxan-2-yloxy)ethyl]imidazol-2-yl]piperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1C1=NC(Br)=CN1CCOC1OCCCC1 AZVOJDLBZIWNNO-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
NVDIEJPTHHHHMI-UHFFFAOYSA-N 4-chloro-5-(1,3-thiazol-2-ylmethylidene)-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C1=2C(Cl)=NC=NC=2NC(=O)C1=CC1=NC=CS1 NVDIEJPTHHHHMI-UHFFFAOYSA-N 0.000 description 1
FRTZJZDPQWFPAL-UHFFFAOYSA-N 4-chloro-5-methyl-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound C1=NC(Cl)=C2C(C)C(=O)NC2=N1 FRTZJZDPQWFPAL-UHFFFAOYSA-N 0.000 description 1
NWXFTSULCLLWEX-UHFFFAOYSA-N 4-chlorospiro[7h-pyrrolo[2,3-d]pyrimidine-5,1'-cyclopentane]-6-one Chemical compound C1=2C(Cl)=NC=NC=2NC(=O)C21CCCC2 NWXFTSULCLLWEX-UHFFFAOYSA-N 0.000 description 1
VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
WFQWTIDVAQNHGR-UHFFFAOYSA-N 5-(3-chloro-4-fluorophenyl)-1h-imidazole Chemical compound C1=C(Cl)C(F)=CC=C1C1=CNC=N1 WFQWTIDVAQNHGR-UHFFFAOYSA-N 0.000 description 1
MOMGLVVLPJNECJ-UHFFFAOYSA-N 5-[4-fluoro-3-(trifluoromethyl)phenyl]-1h-imidazole Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1C1=CNC=N1 MOMGLVVLPJNECJ-UHFFFAOYSA-N 0.000 description 1
UXIBWARNYKBNGU-UHFFFAOYSA-N 5-benzylidene-4-[4-[4-(3-chloro-4-fluorophenyl)-1-[2-(dimethylamino)ethyl]imidazol-2-yl]piperidin-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound CN(C)CCN1C=C(C=2C=C(Cl)C(F)=CC=2)N=C1C(CC1)CCN1C(C1=2)=NC=NC=2NC(=O)C1=CC1=CC=CC=C1 UXIBWARNYKBNGU-UHFFFAOYSA-N 0.000 description 1
JWHGNPMDKLQJJC-UHFFFAOYSA-N 5-benzylidene-4-chloro-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C1=2C(Cl)=NC=NC=2NC(=O)C1=CC1=CC=CC=C1 JWHGNPMDKLQJJC-UHFFFAOYSA-N 0.000 description 1
FHZALEJIENDROK-UHFFFAOYSA-N 5-bromo-1h-imidazole Chemical compound BrC1=CN=CN1 FHZALEJIENDROK-UHFFFAOYSA-N 0.000 description 1
GMMWNTHAIOJBSD-UHFFFAOYSA-N 6-chloro-4-n-(2,3-dimethylphenyl)-2-n,2-n-dimethylpyrimidine-2,4-diamine Chemical compound CN(C)C1=NC(Cl)=CC(NC=2C(=C(C)C=CC=2)C)=N1 GMMWNTHAIOJBSD-UHFFFAOYSA-N 0.000 description 1
VNSFICAUILKARD-UHFFFAOYSA-N 6-chloropyrimidine-4,5-diamine Chemical compound NC1=NC=NC(Cl)=C1N VNSFICAUILKARD-UHFFFAOYSA-N 0.000 description 1
BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Natural products C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
NGQSCHWKUFGWPA-UHFFFAOYSA-N Cl.NN.C(C)N Chemical compound Cl.NN.C(C)N NGQSCHWKUFGWPA-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
CFNOGBSEZGRDEI-UHFFFAOYSA-N FC(C=CC(C1=CN(CCN2CCCC2)C(C2CCNCC2)=N1)=C1)=C1Cl.Cl Chemical compound FC(C=CC(C1=CN(CCN2CCCC2)C(C2CCNCC2)=N1)=C1)=C1Cl.Cl CFNOGBSEZGRDEI-UHFFFAOYSA-N 0.000 description 1
XGCFOZBHINAGSN-UHFFFAOYSA-N FC(C=CC(C1=CN(CCN2CCCC2)C(C2CCNCC2)=N1)=C1)=C1F.Cl Chemical compound FC(C=CC(C1=CN(CCN2CCCC2)C(C2CCNCC2)=N1)=C1)=C1F.Cl XGCFOZBHINAGSN-UHFFFAOYSA-N 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
102000003861 Ribosomal protein S6 Human genes 0.000 description 1
108090000221 Ribosomal protein S6 Proteins 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
KHPWHJVKPZIZRG-CYBMUJFWSA-N [(2r)-1-benzylpiperidin-2-yl]methanol Chemical compound OC[C@H]1CCCCN1CC1=CC=CC=C1 KHPWHJVKPZIZRG-CYBMUJFWSA-N 0.000 description 1
MJMXSNHYUJBWKG-UHFFFAOYSA-N [Cl-].[SH3+].C Chemical compound [Cl-].[SH3+].C MJMXSNHYUJBWKG-UHFFFAOYSA-N 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
229940110282 alimta Drugs 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
NMVVJCLUYUWBSZ-UHFFFAOYSA-N aminomethylideneazanium;chloride Chemical compound Cl.NC=N NMVVJCLUYUWBSZ-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
GZWBYJYRHPKPPI-AREMUKBSSA-N benzyl (2r)-2-[[4-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]imidazol-1-yl]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(C(F)=CC=2)C(F)(F)F)=CN1C[C@@H]1N(C(=O)OCC=2C=CC=CC=2)CCCC1 GZWBYJYRHPKPPI-AREMUKBSSA-N 0.000 description 1
SIONIIVXRCVHFL-OAHLLOKOSA-N benzyl (3r)-3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-1-carboxylate Chemical compound C1[C@H](NC(=O)OC(C)(C)C)CCCN1C(=O)OCC1=CC=CC=C1 SIONIIVXRCVHFL-OAHLLOKOSA-N 0.000 description 1
OPKVUYXYGYRILZ-RUZDIDTESA-N benzyl (3r)-3-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]imidazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(C(F)=CC=2)C(F)(F)F)=CN1[C@H]1CN(C(=O)OCC=2C=CC=CC=2)CCC1 OPKVUYXYGYRILZ-RUZDIDTESA-N 0.000 description 1
JDIGCTFLXLKCBL-UNTBIKODSA-N benzyl (3r)-3-[[2-[4-fluoro-3-(trifluoromethyl)phenyl]-2-oxoethyl]amino]piperidine-1-carboxylate;hydrochloride Chemical compound Cl.C1=C(C(F)(F)F)C(F)=CC=C1C(=O)CN[C@H]1CN(C(=O)OCC=2C=CC=CC=2)CCC1 JDIGCTFLXLKCBL-UNTBIKODSA-N 0.000 description 1
PBFBPDLWODIXHK-GFCCVEGCSA-N benzyl (3r)-3-aminopiperidine-1-carboxylate Chemical compound C1[C@H](N)CCCN1C(=O)OCC1=CC=CC=C1 PBFBPDLWODIXHK-GFCCVEGCSA-N 0.000 description 1
NXLHXKQZPMJMPL-UHFFFAOYSA-N benzyl 2-[(4-methylphenyl)sulfonyloxymethyl]pyrrolidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1N(C(=O)OCC=2C=CC=CC=2)CCC1 NXLHXKQZPMJMPL-UHFFFAOYSA-N 0.000 description 1
GTPRJEAZLBRRCE-UHFFFAOYSA-N benzyl n-[2-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-2-piperidin-4-ylimidazol-1-yl]ethyl]-n-methylcarbamate;dihydrochloride Chemical compound Cl.Cl.C=1C=CC=CC=1COC(=O)N(C)CCN1C=C(C=2C=C(C(F)=CC=2)C(F)(F)F)N=C1C1CCNCC1 GTPRJEAZLBRRCE-UHFFFAOYSA-N 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940088954 camptosar Drugs 0.000 description 1
RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 1
229910000422 cerium(IV) oxide Inorganic materials 0.000 description 1
229960005395 cetuximab Drugs 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 1
229940115080 doxil Drugs 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
229940121647 egfr inhibitor Drugs 0.000 description 1
238000010828 elution Methods 0.000 description 1
229940082789 erbitux Drugs 0.000 description 1
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
229960003750 ethyl chloride Drugs 0.000 description 1
229960005167 everolimus Drugs 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
229940084651 iressa Drugs 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
239000007788 liquid Substances 0.000 description 1
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
229940124302 mTOR inhibitor Drugs 0.000 description 1
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
DWKBWEQGJORTQY-UHFFFAOYSA-N methyl 2-[4-chloro-6-[(2,4-dimethoxyphenyl)methylamino]pyrimidin-5-yl]acetate Chemical compound COC(=O)CC1=C(Cl)N=CN=C1NCC1=CC=C(OC)C=C1OC DWKBWEQGJORTQY-UHFFFAOYSA-N 0.000 description 1
DDCYYCUMAFYDDU-UHFFFAOYSA-N methyl thiohypochlorite Chemical compound CSCl DDCYYCUMAFYDDU-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
IHFZUIBTENSHSH-UHFFFAOYSA-N n,n-dimethoxy-1-phenylmethanamine Chemical compound CON(OC)CC1=CC=CC=C1 IHFZUIBTENSHSH-UHFFFAOYSA-N 0.000 description 1
WWONFUQGBVOKOF-UHFFFAOYSA-N n-(5-bromothiophen-2-yl)sulfonyl-2,4-dichlorobenzamide Chemical compound ClC1=CC(Cl)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(Br)S1 WWONFUQGBVOKOF-UHFFFAOYSA-N 0.000 description 1
QSRNOFDYCBMUHQ-UHFFFAOYSA-N n-(5-bromothiophen-2-yl)sulfonyl-2,4-dichlorobenzamide;sodium Chemical compound [Na].ClC1=CC(Cl)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(Br)S1 QSRNOFDYCBMUHQ-UHFFFAOYSA-N 0.000 description 1
FTNFEHXDETWERN-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-2,6-dimethyl-5-[(4-propan-2-yloxyphenyl)methyl]pyrimidin-4-amine Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 FTNFEHXDETWERN-UHFFFAOYSA-N 0.000 description 1
XHXVAJHZTIXQQD-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-5-[(4-butoxyphenyl)methyl]-2,6-dimethylpyrimidin-4-amine Chemical compound C1=CC(OCCCC)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 XHXVAJHZTIXQQD-UHFFFAOYSA-N 0.000 description 1
DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
125000002560 nitrile group Chemical group 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229960005079 pemetrexed Drugs 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000011027 product recovery Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
239000001294 propane Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
YBBJKCMMCRQZMA-UHFFFAOYSA-N pyrithione Chemical compound ON1C=CC=CC1=S YBBJKCMMCRQZMA-UHFFFAOYSA-N 0.000 description 1
229960002026 pyrithione Drugs 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960001302 ridaforolimus Drugs 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000018553 tannin Nutrition 0.000 description 1
229920001864 tannin Polymers 0.000 description 1
239000001648 tannin Substances 0.000 description 1
229950010853 tasisulam Drugs 0.000 description 1
229960000235 temsirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
XTDXZSGSIMLARD-UHFFFAOYSA-N tert-butyl 2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC=CC=C1 XTDXZSGSIMLARD-UHFFFAOYSA-N 0.000 description 1
JFRONNXPPRHUPJ-UHFFFAOYSA-N tert-butyl 4-(5-phenyl-1h-imidazol-2-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=CC=CC=2)=CN1 JFRONNXPPRHUPJ-UHFFFAOYSA-N 0.000 description 1
WDVJZCFXSHENLM-UHFFFAOYSA-N tert-butyl 4-[1-[2-(oxan-2-yloxy)ethyl]imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC=CN1CCOC1OCCCC1 WDVJZCFXSHENLM-UHFFFAOYSA-N 0.000 description 1
NRYAHTHODPRZKM-UHFFFAOYSA-N tert-butyl 4-[1-[2-[benzyl(methyl)amino]ethyl]-4-(3-chloro-4-fluorophenyl)imidazol-2-yl]piperidine-1-carboxylate Chemical compound C=1C=CC=CC=1CN(C)CCN1C=C(C=2C=C(Cl)C(F)=CC=2)N=C1C1CCN(C(=O)OC(C)(C)C)CC1 NRYAHTHODPRZKM-UHFFFAOYSA-N 0.000 description 1
VBTGHGZYWRPETH-UHFFFAOYSA-N tert-butyl 4-[4-(3,4-difluorophenyl)-1-(2-hydroxyethyl)imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(F)C(F)=CC=2)=CN1CCO VBTGHGZYWRPETH-UHFFFAOYSA-N 0.000 description 1
IPUQWOPWTHYARO-UHFFFAOYSA-N tert-butyl 4-[4-(3,4-difluorophenyl)-1-[2-[2-hydroxyethyl(methyl)amino]ethyl]imidazol-2-yl]piperidine-1-carboxylate Chemical compound OCCN(C)CCN1C=C(C=2C=C(F)C(F)=CC=2)N=C1C1CCN(C(=O)OC(C)(C)C)CC1 IPUQWOPWTHYARO-UHFFFAOYSA-N 0.000 description 1
UWJUDLBHRWOJBK-UHFFFAOYSA-N tert-butyl 4-[4-(3-chloro-4-fluorophenyl)-1-(2-hydroxyethyl)imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(Cl)C(F)=CC=2)=CN1CCO UWJUDLBHRWOJBK-UHFFFAOYSA-N 0.000 description 1
BGTXTMTZJNHWEC-UHFFFAOYSA-N tert-butyl 4-[4-(3-chloro-4-fluorophenyl)-1-[2-(oxan-2-yloxy)ethyl]imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(Cl)C(F)=CC=2)=CN1CCOC1OCCCC1 BGTXTMTZJNHWEC-UHFFFAOYSA-N 0.000 description 1
TWOALUJRVBCHOK-UHFFFAOYSA-N tert-butyl 4-[4-(3-chloro-4-fluorophenyl)-1-[2-[methyl(phenylmethoxycarbonyl)amino]ethyl]imidazol-2-yl]piperidine-1-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)N(C)CCN1C=C(C=2C=C(Cl)C(F)=CC=2)N=C1C1CCN(C(=O)OC(C)(C)C)CC1 TWOALUJRVBCHOK-UHFFFAOYSA-N 0.000 description 1
BRESDBJDSIDSCI-UHFFFAOYSA-N tert-butyl 4-[4-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]imidazol-2-yl]piperidine-1-carboxylate Chemical compound CN(C)CCN1C=C(C=2C=CC(Cl)=CC=2)N=C1C1CCN(C(=O)OC(C)(C)C)CC1 BRESDBJDSIDSCI-UHFFFAOYSA-N 0.000 description 1
NMEQWGRWUXWOEV-UHFFFAOYSA-N tert-butyl 4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-(2-methylsulfonyloxyethyl)imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(C(F)=CC=2)C(F)(F)F)=CN1CCOS(C)(=O)=O NMEQWGRWUXWOEV-UHFFFAOYSA-N 0.000 description 1
VHZIDRWWTUPRNF-UHFFFAOYSA-N tert-butyl 4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-phenylmethoxycarbonylpyrrolidin-2-yl)methyl]imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(C(F)=CC=2)C(F)(F)F)=CN1CC1N(C(=O)OCC=2C=CC=CC=2)CCC1 VHZIDRWWTUPRNF-UHFFFAOYSA-N 0.000 description 1
ONYRTMPRJOSLJZ-LJQANCHMSA-N tert-butyl 4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(3r)-1-methylpiperidin-3-yl]imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1N(C)CCC[C@H]1N1C(C2CCN(CC2)C(=O)OC(C)(C)C)=NC(C=2C=C(C(F)=CC=2)C(F)(F)F)=C1 ONYRTMPRJOSLJZ-LJQANCHMSA-N 0.000 description 1
KCIDDIUDFKDNHH-HXUWFJFHSA-N tert-butyl 4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[2-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl]imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2C=C(C(F)=CC=2)C(F)(F)F)=CN1CCN1[C@@H](CO)CCC1 KCIDDIUDFKDNHH-HXUWFJFHSA-N 0.000 description 1
LXLZQDZNMVDJPW-UHFFFAOYSA-N tert-butyl 4-[4-bromo-1-[2-(oxan-2-yloxy)ethyl]imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(Br)=CN1CCOC1OCCCC1 LXLZQDZNMVDJPW-UHFFFAOYSA-N 0.000 description 1
ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
USYCVFFWCMHPPG-UHFFFAOYSA-N tert-butyl 4-sulfanylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(S)CC1 USYCVFFWCMHPPG-UHFFFAOYSA-N 0.000 description 1
FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
229930183279 tetramycin Natural products 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
HJXJNSKEOFNHCU-UHFFFAOYSA-N thiohypobromous acid Chemical compound BrS HJXJNSKEOFNHCU-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
229940100411 torisel Drugs 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
238000005406 washing Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

TW098136731A 2008-11-11 2009-10-29 Ａｋｔ及ｐ７０ｓ６激酶抑制劑 TWI422587B (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11327308P	2008-11-11	2008-11-11

Publications (2)

Publication Number	Publication Date
TW201022268A TW201022268A (en)	2010-06-16
TWI422587B true TWI422587B (zh)	2014-01-11

Family

ID=41402451

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW098136731A TWI422587B (zh)	2008-11-11	2009-10-29	Ａｋｔ及ｐ７０ｓ６激酶抑制劑

Country Status (36)

Country	Link
US (1)	US8148387B2 (2)
EP (1)	EP2358710B1 (2)
JP (1)	JP5432275B2 (2)
KR (1)	KR101334460B1 (2)
CN (1)	CN102216302B (2)
AR (1)	AR074072A1 (2)
AU (1)	AU2009314324B2 (2)
BR (1)	BRPI0921916A2 (2)
CA (1)	CA2743019C (2)
CO (1)	CO6382114A2 (2)
CR (1)	CR20110240A (2)
CY (1)	CY1113409T1 (2)
DK (1)	DK2358710T3 (2)
DO (1)	DOP2011000129A (2)
EA (1)	EA018947B1 (2)
EC (1)	ECSP11011048A (2)
ES (1)	ES2391704T3 (2)
HN (1)	HN2011001247A (2)
HR (1)	HRP20120738T1 (2)
IL (1)	IL211940A (2)
JO (1)	JO2822B1 (2)
MA (1)	MA32776B1 (2)
MX (1)	MX2011005000A (2)
MY (1)	MY161461A (2)
NZ (1)	NZ592062A (2)
PA (1)	PA8846901A1 (2)
PE (1)	PE20110807A1 (2)
PL (1)	PL2358710T3 (2)
PT (1)	PT2358710E (2)
RS (1)	RS52520B (2)
SI (1)	SI2358710T1 (2)
TN (1)	TN2011000207A1 (2)
TW (1)	TWI422587B (2)
UA (1)	UA100190C2 (2)
WO (1)	WO2010056563A1 (2)
ZA (1)	ZA201102549B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10201402867TA (en)	2009-07-02	2014-08-28	Sanofi Sa	Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
EA020151B1 (ru) *	2009-10-23	2014-09-30	Эли Лилли Энд Компани	Ингибиторы akt и фармацевтические составы, их содержащие
HUE026323T2 (en)	2011-04-07	2016-05-30	Bayer Ip Gmbh	Imidazopyridazines as akt kinase inhibitors
ES2547687T3 (es) *	2011-07-09	2015-10-08	Xuanzhu Pharma Co., Ltd.	Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma
PT2755965T (pt)	2011-09-12	2017-11-02	Merck Patent Gmbh	Novas imidazol aminas como moduladores da atividade quinase
US9321760B2 (en)	2011-09-12	2016-04-26	Merck Patent Gmbh	Aminopyrimidine derivatives for use as modulators of kinase activity
EP2920154B1 (en)	2012-11-16	2017-10-11	Merck Patent GmbH	Novel imidazol-piperidinyl derivatives as modulators of kinase activity
US9580443B2 (en)	2012-11-16	2017-02-28	Merck Patent Gmbh	Heterocyclic derivatives as modulators of kinase activity
AR095202A1 (es) *	2013-03-11	2015-09-30	Merck Patent Gmbh	Heterociclos como moduladores de la actividad quinasa
MX2016010268A (es) *	2014-02-11	2016-10-13	Merck Patent Gmbh	Pirimidinimidazolaminas como modulares de actividad de cinasa.
TW201718574A (zh)	2015-08-12	2017-06-01	美國禮來大藥廠	Ｃｇｒｐ受體拮抗劑
PT3459953T (pt)	2016-05-20	2021-07-29	Taiho Pharmaceutical Co Ltd	Novo derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona
CN115397815B (zh) *	2020-03-17	2024-06-14	江苏恒瑞医药股份有限公司	稠合二环类衍生物、其制备方法及其在医药上的应用
CN113444110B (zh) *	2020-03-25	2023-05-12	江苏恒瑞医药股份有限公司	四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
JP2024535857A (ja)	2021-09-17	2024-10-02	江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司	縮合二環系誘導体の薬学的に許容される塩、結晶及びそれらの調製方法
WO2024009977A1 (ja) *	2022-07-05	2024-01-11	大鵬薬品工業株式会社	５Ｈ－ピロロ［２，３－ｄ］ピリミジン－６（７Ｈ）－オン及びその塩体の結晶

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006091450A1 (en) *	2005-02-18	2006-08-31	Lexicon Genetics Incorporated	4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
WO2008075109A1 (en) *	2006-12-21	2008-06-26	Astex Therapeutics Limited	Substituted piperidines having protein kinase inhibiting activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005117909A2 (en)	2004-04-23	2005-12-15	Exelixis, Inc.	Kinase modulators and methods of use
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja)	2004-12-28	2013-08-28	エグゼリクシス，インコーポレイテッド	免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
US20090325924A1 (en)	2005-06-30	2009-12-31	Stuart Edward	GPCR Agonists
EP2037931A2 (en)	2006-04-25	2009-03-25	Astex Therapeutics Limited	Pharmaceutical combinations of pk inhibitors and other active agents
DK3421471T3 (da)	2006-04-25	2021-06-14	Astex Therapeutics Ltd	Purin- og deazapurinderivater som farmaceutiske forbindelser
WO2008012635A2 (en)	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents
UA99284C2 (ru)	2007-05-11	2012-08-10	Елі Ліллі Енд Компані	ИНГИБИТОРЫ р70 S6-КИНАЗЫ

2009
- 2009-10-28 AR ARP090104158A patent/AR074072A1/es unknown
- 2009-10-29 PA PA20098846901A patent/PA8846901A1/es unknown
- 2009-10-29 TW TW098136731A patent/TWI422587B/zh not_active IP Right Cessation
- 2009-10-29 JO JO2009400A patent/JO2822B1/en active
- 2009-11-03 CN CN2009801449532A patent/CN102216302B/zh active Active
- 2009-11-03 US US12/611,139 patent/US8148387B2/en active Active
- 2009-11-03 PE PE2011001018A patent/PE20110807A1/es not_active Application Discontinuation
- 2009-11-03 DK DK09744896.3T patent/DK2358710T3/da active
- 2009-11-03 NZ NZ592062A patent/NZ592062A/xx not_active IP Right Cessation
- 2009-11-03 HR HRP20120738AT patent/HRP20120738T1/hr unknown
- 2009-11-03 BR BRPI0921916A patent/BRPI0921916A2/pt not_active IP Right Cessation
- 2009-11-03 PL PL09744896T patent/PL2358710T3/pl unknown
- 2009-11-03 ES ES09744896T patent/ES2391704T3/es active Active
- 2009-11-03 JP JP2011536383A patent/JP5432275B2/ja active Active
- 2009-11-03 EP EP09744896A patent/EP2358710B1/en active Active
- 2009-11-03 RS RS20120443A patent/RS52520B/sr unknown
- 2009-11-03 PT PT09744896T patent/PT2358710E/pt unknown
- 2009-11-03 MY MYPI2011002030A patent/MY161461A/en unknown
- 2009-11-03 SI SI200930348T patent/SI2358710T1/sl unknown
- 2009-11-03 AU AU2009314324A patent/AU2009314324B2/en not_active Ceased
- 2009-11-03 CA CA2743019A patent/CA2743019C/en not_active Expired - Fee Related
- 2009-11-03 UA UAA201105367A patent/UA100190C2/ru unknown
- 2009-11-03 EA EA201170680A patent/EA018947B1/ru not_active IP Right Cessation
- 2009-11-03 WO PCT/US2009/063020 patent/WO2010056563A1/en not_active Ceased
- 2009-11-03 MX MX2011005000A patent/MX2011005000A/es active IP Right Grant
- 2009-11-03 KR KR1020117010569A patent/KR101334460B1/ko not_active Expired - Fee Related
2011
- 2011-03-24 IL IL211940A patent/IL211940A/en not_active IP Right Cessation
- 2011-04-06 ZA ZA2011/02549A patent/ZA201102549B/en unknown
- 2011-04-25 TN TN2011000207A patent/TN2011000207A1/fr unknown
- 2011-05-03 HN HN2011001247A patent/HN2011001247A/es unknown
- 2011-05-06 CR CR20110240A patent/CR20110240A/es unknown
- 2011-05-09 DO DO2011000129A patent/DOP2011000129A/es unknown
- 2011-05-09 MA MA33822A patent/MA32776B1/fr unknown
- 2011-05-11 EC EC2011011048A patent/ECSP11011048A/es unknown
- 2011-05-12 CO CO11058555A patent/CO6382114A2/es active IP Right Grant
2012
- 2012-10-05 CY CY20121100928T patent/CY1113409T1/el unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006091450A1 (en) *	2005-02-18	2006-08-31	Lexicon Genetics Incorporated	4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
WO2008075109A1 (en) *	2006-12-21	2008-06-26	Astex Therapeutics Limited	Substituted piperidines having protein kinase inhibiting activity

Also Published As

Publication number	Publication date
ECSP11011048A (es)	2011-06-30
WO2010056563A1 (en)	2010-05-20
US20100120801A1 (en)	2010-05-13
MY161461A (en)	2017-04-14
IL211940A0 (en)	2011-06-30
CY1113409T1 (el)	2016-06-22
EA201170680A1 (ru)	2011-12-30
SI2358710T1 (sl)	2012-11-30
JP2012508274A (ja)	2012-04-05
RS52520B (sr)	2013-04-30
DK2358710T3 (da)	2012-09-03
HN2011001247A (es)	2013-05-20
MA32776B1 (fr)	2011-11-01
DOP2011000129A (es)	2016-02-29
KR101334460B1 (ko)	2013-12-02
IL211940A (en)	2014-01-30
BRPI0921916A2 (pt)	2015-12-29
NZ592062A (en)	2013-03-28
TN2011000207A1 (en)	2012-12-17
PT2358710E (pt)	2012-10-01
CO6382114A2 (es)	2012-02-15
EP2358710B1 (en)	2012-08-15
AU2009314324A1 (en)	2010-05-20
EA018947B1 (ru)	2013-11-29
JP5432275B2 (ja)	2014-03-05
HRP20120738T1 (hr)	2012-10-31
EP2358710A1 (en)	2011-08-24
CR20110240A (es)	2011-06-09
KR20110074578A (ko)	2011-06-30
ES2391704T3 (es)	2012-11-29
PL2358710T3 (pl)	2012-12-31
MX2011005000A (es)	2011-05-25
TW201022268A (en)	2010-06-16
CA2743019A1 (en)	2010-05-20
US8148387B2 (en)	2012-04-03
CN102216302B (zh)	2013-08-21
ZA201102549B (en)	2012-09-26
CN102216302A (zh)	2011-10-12
PA8846901A1 (es)	2010-06-28
AR074072A1 (es)	2010-12-22
PE20110807A1 (es)	2011-10-31
CA2743019C (en)	2013-08-13
JO2822B1 (en)	2014-09-15
HK1158203A1 (en)	2012-07-13
UA100190C2 (en)	2012-11-26
AU2009314324B2 (en)	2013-06-20

Legal Events

Date	Code	Title	Description
2018-10-11	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
TWI422587B (zh)	2014-01-11	Ａｋｔ及ｐ７０ｓ６激酶抑制劑
CN113423703B (zh)	2024-08-02	含氮杂环类衍生物调节剂、其制备方法和应用
JP6903796B2 (ja)	2021-07-14	Ｆｇｆｒ４阻害剤としての二環式複素環
KR102507287B1 (ko)	2023-03-07	Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
TWI592413B (zh)	2017-07-21	作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
TW202122396A (zh)	2021-06-16	ＫＲａｓＧ１２Ｄ抑制劑
JP2021519783A (ja)	2021-08-12	Ｍａｔ２ａの複素二環式阻害剤、およびがんの治療のための使用方法
JP2022542396A (ja)	2022-10-03	Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
KR20130116358A (ko)	2013-10-23	Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
EP3478687A1 (en)	2019-05-08	Pyrazolopyrimidine derivatives as kinase inhibitor
EP4472739A1 (en)	2024-12-11	Imidazole macrocycles for the treatment of autoimmune disease
AU2013295906A1 (en)	2015-02-19	Novel heteroaryl and heterocycle compounds, composition and methods thereof
KR20160150006A (ko)	2016-12-28	헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
KR101767260B1 (ko)	2017-08-10	피리미도 옥사진 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
HK1158203B (en)	2012-12-14	Akt and p70 s6 kinase inhibitors

TWI422587B - Ａｋｔ及ｐ７０ ｓ６激酶抑制劑 - Google Patents